Prot: KD025-209: A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis

  • Varga, John (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/11/19 → 10/11/22

Funding

  • Kadmon Corporation, LLC ((OE) Prot: KD025-209)